Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

A retrospective cohort study of 64 patients with Philadelphia chromosome–negative myeloproliferative neoplasms found that ropeginterferon alfa-2b-njft achieved hematologic and molecular efficacy in polycythemia vera, essential thrombocythemia, and prefibrotic myelofibrosis (MF), but responses were more limited in overt MF. Patients with MF harboring high-molecular-risk mutations derived little benefit and experienced higher rates of adverse events.